FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Stewart Christopher P.						2. Issuer Name and Ticker or Trading Symbol Bionano Genomics, Inc [BNGO]									ck all app Direc	,	ng Per	rson(s) to Is 10% O Other (s	wner
	C/O BIONANO GENOMICS, INC.							3. Date of Earliest Transaction (Month/Day/Year) 01/22/2021								Chief Fina		below)	
9540 TOWNE CENTRE DRIVE, SUITE 100					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street) SAN DII	EGO CA	A 9	2121											Line) X	Form	in filed by One Reporting Person in filed by More than One Reporting			on
(City)	(St	ate) (2	Zip)												F 6130) i i			
		Table	I - Nor	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	oosed of	, or E	Benef	iciall	y Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day				Execution		cution ny	Date,			Disposed	Securities Acquired (Aisposed Of (D) (Instr. 3			Benefic	ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(3 4)
Common Stock 01/22/2					2021				A ⁽¹⁾		8,000	A	A .	\$6	8	8,000		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, ity or Exercise (Month/Day/Year) if any			4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Str.	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Own Forn Direc or In (I) (Ir	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code		v	(A) (D)		Date Exercisable		Expiration Date	or Numb of Title Share							

Explanation of Responses:

1. Acquired from the Issuer pursuant to an Underwriting Agreement dated January 20, 2021 with a closing date of January 22, 2021. The Underwriting Agreement and the issuance of the securities thereunder was approved by the Issuer's Board of Directors.

Remarks:

/s/ Christopher Stewart

01/22/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.